You will not be paid for being in this study.
Close research trial
No
Eligibility Requirements
  • Age 18 years or older
  • Confirmed COVID-19 infection
[email protected] A Phase II Single-Center, Open-Label, Safety and Efficacy Study of Etoposide in Patients with COVID-19 Infection (IRB: H-40102) NCT04356690 H-40102

This is a randomized, open-label phase II study designed to evaluate the safety and efficacy of etoposide in patients with the 2019 novel coronavirus (COVID-19) infection. Randomization will be performed with a 3:1 allocation ratio. Treatment will be comprised of etoposide administered intravenously at a dose of 150 mg/m2 on days one and four in patients with COVID-19 infection meeting eligibility criteria.

Subsequent doses of etoposide will be allowed if the investigator and treating physician believe the patient had clinical benefit from etoposide therapy but subsequently has evidence of recurrent clinical deterioration. Subjects randomized to control will receive standard of care treatment. No placebo will be used.